Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02318368
Title A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors AVEO Pharmaceuticals, Inc, Biodesix

lung non-small cell carcinoma



Erlotinib + Ficlatuzumab

Age Groups: adult
Covered Countries USA | ITA

No variant requirements are available.